
Sanofi and Regeneron Pharmaceuticals have announced that their Phase III ODYSSEY ESCAPE clinical trial evaluating Praluent (alirocumab) met its primary …
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour

